Loading...
Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance)
BACKGROUND: This multicenter, randomized phase 2 trial evaluated complete response (CR), efficacy, and safety with ofatumumab and bendamustine and ofatumumab, bendamustine, and bortezomib in patients with untreated, high-risk follicular lymphoma (FL). METHODS: Patients with grade 1–3a FL and either...
Na minha lista:
| Udgivet i: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6744328/ https://ncbi.nlm.nih.gov/pubmed/31174236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32289 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|